Chemours (NYSE: CC) installs Mary Cranston as board chair, Cowan lead director

Rhea-AI Filing Summary

The Chemours Company reported changes to its board leadership. The Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan as Lead Independent Director, both effective September 2, 2025. These moves follow the departure of former Chair Dawn Farrell, who has accepted a role with the Canadian government as Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act. The filing confirms this is a governance update and does not discuss changes to the company’s business strategy or financial results.

Insights

Corporate governance analyst

Chemours updates board leadership with new chair and lead director.

The Chemours Company has restructured its board leadership by naming Independent Director Mary Cranston as Chair of the Board and Alister Cowan as Lead Independent Director, effective September 2, 2025. This represents a shift in how independent directors oversee and coordinate the board’s work.

The change follows the departure of former Chair Dawn Farrell, who is leaving to become Chief Executive Officer of the Canadian government’s new Major Projects Office under the Building Canada Act. The filing presents this as a transition tied to her new public role rather than to company performance.

The disclosure focuses solely on board roles and does not provide information about strategic or financial impacts. Any implications for oversight or long-term direction would depend on future decisions and disclosures from the reconstituted board.

false000162722300016272232025-09-022025-09-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

September 2, 2025

Date of Report (Date of Earliest Event Reported)

The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-36794		46-4845564
(State or Other Jurisdiction		(Commission		(I.R.S. Employer
Of Incorporation)		File Number)		Identification No.)

1007 Market Street

Wilmington, Delaware 19801

(Address of principal executive offices)

Registrant’s telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Exchange on Which Registered
Common Stock ($0.01 par value)		CC		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

The Chemours Company (the “Company”) announced that its Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan to the role of Lead Independent Director, effective September 2, 2025. These appointments follow the departure of Dawn Farrell, who has accepted a position with the Canadian government as the Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY
By:		/s/ Shane Hostetter
		Shane Hostetter
		Senior Vice President, Chief Financial Officer
Date:		September 3, 2025

FAQ

What board leadership changes did The Chemours Company (CC) announce?

The Chemours Company announced that Independent Director Mary Cranston has been appointed as Chair of the Board and Alister Cowan has been appointed as Lead Independent Director, effective September 2, 2025.

When do the new Chemours (CC) board appointments take effect?

The appointments of Mary Cranston as Chair of the Board and Alister Cowan as Lead Independent Director at The Chemours Company are effective as of September 2, 2025.

Why did Dawn Farrell leave The Chemours Company (CC) board?

The filing states that Dawn Farrell departed the board after accepting a position with the Canadian government as Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act.

Does the Chemours (CC) 8-K mention any financial or strategic changes?

The 8-K describes board leadership changes under Item 8.01 Other Events and does not discuss changes to The Chemours Company’s financial results or business strategy.

What role will Alister Cowan serve on Chemours (CC) board?

Alister Cowan has been appointed to the role of Lead Independent Director on The Chemours Company’s Board of Directors, effective September 2, 2025.

Under which SEC item did Chemours (CC) disclose the board changes?

The Chemours Company disclosed these board leadership changes under Item 8.01 Other Events of its Form 8-K.